miR‑221‑3p and miR‑222‑3p regulate the SOCS3/STAT3 signaling pathway to downregulate the expression of NIS and reduce radiosensitivity in thyroid cancer

Ye,Ting; Zhong,Lili; Ye,Xuemei; Liu,Jie; Li,Linfa; Yi,Heqing

doi:10.3892/etm.2021.10084

miR‑221‑3p and miR‑222‑3p regulate the SOCS3/STAT3 signaling pathway to downregulate the expression of NIS and reduce radiosensitivity in thyroid cancer

Authors:
- Ting Ye
- Lili Zhong
- Xuemei Ye
- Jie Liu
- Linfa Li
- Heqing Yi
View Affiliations

Affiliations: Department of Nuclear Medicine, Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310021, P.R. China, Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, Second Hospital of Jilin University, Changchun, Jilin 130022, P.R. China
Published online on: April 19, 2021 https://doi.org/10.3892/etm.2021.10084
Article Number: 652
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression levels of microRNA (miR)‑221‑3p and miR‑222‑3p in thyroid cancer have been found to be upregulated compared with those in normal tissues. The present study aimed to determine the effects and potential underlying mechanisms of miR‑221‑3p and miR‑222‑3p on the regulation of radioactive iodine (131I) uptake and radiosensitivity of thyroid cancer cells. The potential regulatory target genes of miR‑221‑3p and miR‑222‑3p were predicted by bioinformatics analysis, and reverse transcription‑quantitative polymerase chain reaction was used to verify miR‑221‑3p, miR‑222‑3p and target gene expression levels in thyroid cancer tissues and cell lines. Overexpression of miR‑221‑3p or miR‑222‑3p in cell models was performed using lentivirus infection. Knockdown of miR‑221‑3p and miR‑222‑3p in cells was achieved using oligonucleotide inhibitor transfection. Western blotting was used to analyze the expression levels of target proteins. In addition, the effects of miR‑221‑3p and miR‑222‑3p on the radiosensitivity of thyroid cancer cells were verified using a colony formation assay. The results of the present study revealed that the expression levels of miR‑221‑3p and miR‑222‑3p were significantly upregulated, while the expression levels of suppressor of cytokine signaling 3 (SOCS3) were downregulated in thyroid cancer tissues. Furthermore, miR‑221‑3p and miR‑222‑3p overexpression downregulated the expression levels of SOCS3, E‑cadherin and solute carrier family 5 member 5 (NIS), and upregulated the expression levels of phosphorylated STAT3 and vimentin. Following the overexpression of miR‑221‑3p or miR‑222‑3p in the FTC133 and TPC1 cell lines, their radiosensitivity was suppressed. In conclusion, the findings of the present study suggested that miR‑221‑3p and miR‑222‑3p may downregulate the expression levels of NIS and promote radioresistance. The potential mechanism was hypothesized to be associated with the miR‑221‑3p and miR‑222‑3p targeting of the SOCS3 gene, which may subsequently activate the STAT3 signaling pathway.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar : Erratum in: CA Cancer J Clin 70, 313, 2020.
2	Song HJ, Qiu ZL, Shen CT, Wei WJ and Luo QY: Pulmonary metastases in differentiated thyroid cancer: Efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol. 173:399–408. 2015.PubMed/NCBI View Article : Google Scholar
3	Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, et al: Cancer Genome Atlas Research Network: Integrated genomic characterization of papillary thyroid carcinoma. Cell. 159:676–690. 2014.PubMed/NCBI View Article : Google Scholar
4	Van Nostrand D: Radioiodine refractory differentiated thyroid cancer: Time to update the classifications. Thyroid. 28:1083–1093. 2018.PubMed/NCBI View Article : Google Scholar
5	Treiber T, Treiber N and Meister G: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019.PubMed/NCBI View Article : Google Scholar : Erratum in: Nat Rev Mol Cell Biol 19, 808, 2018.
6	Tsikrika FD, Avgeris M, Levis PK, Tokas T, Stravodimos K and Scorilas A: miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression. Genes Chromosomes Cancer. 57:150–161. 2018.PubMed/NCBI View Article : Google Scholar
7	Chen WX, Hu Q, Qiu MT, Zhong SL, Xu JJ, Tang JH and Zhao JH: miR-221/222: Promising biomarkers for breast cancer. Tumour Biol. 34:1361–1370. 2013.PubMed/NCBI View Article : Google Scholar
8	Amini S, Abak A, Sakhinia E and Abhari A: MicroRNA-221 and microRNA-222 in common human cancers: Expression, function, and triggering of tumor progression as a key modulator. Lab Med. 50:333–347. 2019.PubMed/NCBI View Article : Google Scholar
9	Xu CH, Liu Y, Xiao LM, Chen LK, Zheng SY, Zeng EM, Li DH and Li YP: Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway. J Cell Physiol. 234:22272–22284. 2019.PubMed/NCBI View Article : Google Scholar
10	Jikuzono T, Kawamoto M, Yoshitake H, Kikuchi K, Akasu H, Ishikawa H, Hirokawa M, Miyauchi A, Tsuchiya S, Shimizu K, et al: The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol. 42:1858–1868. 2013.PubMed/NCBI View Article : Google Scholar
11	Zhang X, Mao H and Lv Z: MicroRNA role in thyroid cancer pathogenesis. Front Biosci. 18:734–739. 2013.PubMed/NCBI View Article : Google Scholar
12	Braun J, Hoang-Vu C, Dralle H and Hüttelmaier S: Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 29:4237–4244. 2010.PubMed/NCBI View Article : Google Scholar
13	Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K, Li Y, Song E, et al: Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 97:2084–2092. 2012.PubMed/NCBI View Article : Google Scholar
14	Gómez-Pérez AM, Cornejo Pareja IM, García Alemán J, Coín Aragüez L, Sebastián Ochoa A, Alcaide Torres J, Molina Vega M, Clu Fernández C, Mancha Doblas I and Tinahones FJ: New molecular biomarkers in differentiated thyroid carcinoma: Impact of miR-146, miR-221 and miR-222 levels in the evolution of the disease. Clin Endocrinol (Oxf). 91:187–194. 2019.PubMed/NCBI View Article : Google Scholar
15	Ravegnini G, Cargnin S, Sammarini G, Zanotti F, Bermezo JL, Hrelia P, Terrazzino S and Angelini S: Prognostic role of miR-221 and miR-222 expression in cancer patients: A systematic review and meta-analysis. Cancers (Basel). 11(970)2019.PubMed/NCBI View Article : Google Scholar
16	Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, et al: Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133⁺ cells. J Pharmacol Exp Ther. 341:410–423. 2012.PubMed/NCBI View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
18	Kozomara A, Birgaoanu M and Griffiths-Jones S: miRBase: From microRNA sequences to function. Nucleic Acids Res. 47 (D1):D155–D162. 2019.PubMed/NCBI View Article : Google Scholar
19	TargetScanHuman 5.2 Custom. http://www.targetscan.org/vert_50/seedmatch.html. Accessed April 14, 2021.
20	Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007.PubMed/NCBI View Article : Google Scholar
21	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319. 2006.PubMed/NCBI View Article : Google Scholar
22	Wu C, Guo E, Ming J, Sun W, Nie X, Sun L, Peng S, Luo M, Liu D, Zhang L, et al: Radiation-induced DNMT3B promotes radioresistance in nasopharyngeal carcinoma through methylation of p53 and p21. Mol Ther Oncolytics. 17:306–319. 2020.PubMed/NCBI View Article : Google Scholar
23	Xie C, Wu Y, Fei Z, Fang Y, Xiao S and Su H: MicroRNA-1275 induces radiosensitization in oesophageal cancer by regulating epithelial-to-mesenchymal transition via Wnt/β-catenin pathway. J Cell Mol Med. 24:747–759. 2020.PubMed/NCBI View Article : Google Scholar
24	Zhou S, Zhang M, Zhou C, Wang W, Yang H and Ye W: The role of epithelial-mesenchymal transition in regulating radioresistance. Crit Rev Oncol Hematol. 150(102961)2020.PubMed/NCBI View Article : Google Scholar
25	Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson M, Epperly M and Levina V: Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer. 12(94)2013.PubMed/NCBI View Article : Google Scholar
26	Zhao Y, Zhong L and Yi H: A review on the mechanism of iodide metabolic dysfunction in differentiated thyroid cancer. Mol Cell Endocrinol. 479:71–77. 2019.PubMed/NCBI View Article : Google Scholar
27	Marini F, Luzi E and Brandi ML: MicroRNA role in thyroid cancer development. J Thyroid Res. 2011(407123)2011.PubMed/NCBI View Article : Google Scholar
28	Li S, Li Q, Lü J, Zhao Q, Li D, Shen L, Wang Z, Liu J, Xie D, Cho WC, et al: Targeted inhibition of miR-221/222 promotes cell sensitivity to cisplatin in triple-negative breast cancer MDA-MB-231 cells. Front Genet. 10(1278)2020.PubMed/NCBI View Article : Google Scholar
29	Ying X, Wu Q, Wu X, Zhu Q and Wang X, Jiang L, Chen X and Wang X: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7:43076–43087. 2016.PubMed/NCBI View Article : Google Scholar
30	Xie J, Wen JT, Xue XJ, Zhang KP, Wang XZ and Cheng HH: miR-221 inhibits proliferation of pancreatic cancer cells via down regulation of SOCS3. Eur Rev Med Pharmacol Sci. 22:1914–1921. 2018.PubMed/NCBI View Article : Google Scholar
31	Zhou QY, Peng PL and Xu YH: miR-221 affects proliferation and apoptosis of gastric cancer cells through targeting SOCS3. Eur Rev Med Pharmacol Sci. 24(7565)2020.PubMed/NCBI View Article : Google Scholar
32	Wang H, Zhan M, Liu Q and Wang J: Glycochenodeoxycholate promotes the metastasis of gallbladder cancer cells by inducing epithelial to mesenchymal transition via activation of SOCS3/JAK2/STAT3 signaling pathway. J Cell Physiol. 235:1615–1623. 2020.PubMed/NCBI View Article : Google Scholar
33	Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M and Santisteban P: The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 69:8317–8325. 2009.PubMed/NCBI View Article : Google Scholar
34	Zhou QX, Jiang XM, Wang ZD, Li CL and Cui YF: Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis. Med Oncol. 32(105)2015.PubMed/NCBI View Article : Google Scholar